Evidence map›Paper›PMID 32461072›Full record

ArticleEuropean urology2020

Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer.

Amar U Kishan, Tahmineh Romero, Mohammed Alshalalfa, Yang Liu, Phuoc T Tran, Nicholas G Nickols, Huihui Ye, Dipti Sajed, Matthew B Rettig, Robert E Reiter and 21 more

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02609269 (Prospective Expression Analysis Using The Decipher Genomics Resource for Intelligent Discovery), which is not on this map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02609269 enrolling by invitationnot on this map

Prospective Expression Analysis Using The Decipher Genomics Resource for Intelligent Discovery (GRID)® and Data Sharing Program

Typeobservational_patient_registrySponsorGenomeDx Biosciences CorpRan2015 to 2040Enrolled1,000,000ConditionsProstate Cancer, Bladder Cancer, Renal CancerArmsDecipher Cancer Classifier
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. The Transcriptomic Profiles ofInternational journal of molecular sciences · 2023
    Article
  8. Review
  9. Article
  10. Article
  11. Observational
  12. Review
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

31 authors at 12 institutions in 1 country.

Amar U KishanDepartment of Radiation Oncology, University of California, Los Angeles, CA, USA; Department of Urology, University of California, Los Angeles, CA, USA. Electronic address: aukishan@mednet.ucla.edu.
Tahmineh RomeroStatistics Core, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Mohammed AlshalalfaDepartment of Radiation Oncology, Helen Diller Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Yang LiuDecipher Biosciences, San Diego, CA, USA.
Phuoc T TranDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Nicholas G NickolsDepartment of Radiation Oncology, University of California, Los Angeles, CA, USA; Department of Radiation Oncology, Veteran Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA.
Huihui YeDepartment of Pathology, University of California, Los Angeles, CA, USA.
Dipti SajedDepartment of Pathology, University of California, Los Angeles, CA, USA.
Matthew B RettigDivision of Hematology and Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA; Division of Hematology and Oncology, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA.
Robert E ReiterDepartment of Urology, University of California, Los Angeles, CA, USA.
Isla P GarrawayDepartment of Urology, University of California, Los Angeles, CA, USA; Division of Urology, Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, CA, USA.
Daniel E SprattDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Steven J FreedlandDepartment of Surgery, Division of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Department of Surgery, Division of Urology, Veteran Affairs Healthcare System, Durham, NC, USA.
Xin ZhaoDecipher Biosciences, San Diego, CA, USA.
Ziwen LiDecipher Biosciences, San Diego, CA, USA.
Matthew DeekDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Julie LivingstoneDepartment of Radiation Oncology, University of California, Los Angeles, CA, USA.
Brandon A MahalDepartment of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Paul L NguyenDepartment of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Felix Y FengDepartment of Radiation Oncology, Helen Diller Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Robert B DenDepartment of Radiation Oncology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA.
Edward M SchaefferDepartment of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Tamara L LotanDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
R Jeffrey KarnesDepartment of Urology, Mayo Clinic, Rochester, MN, USA.
Eric A KleinGlickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA.
Ashley E RossTexas Urology Specialists, Dallas, TX, USA.
Tristan GroganStatistics Core, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Elai DavicioniDecipher Biosciences, San Diego, CA, USA.
David ElashoffStatistics Core, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Paul C BoutrosDepartment of Urology, University of California, Los Angeles, CA, USA; Department of Human Genetics, University of California, Los Angeles, CA, USA.
Joanne B WeidhaasDepartment of Radiation Oncology, University of California, Los Angeles, CA, USA.
University of California, Los Angeles · USCoherus BioSciences (United States) · USJohns Hopkins University · USBrigham and Women's Hospital · USUniversity of California, San Francisco · USCedars-Sinai Medical Center · USCleveland Clinic · USDermatology Specialists · USMayo Clinic in Arizona · USNorthwestern University · USThomas Jefferson University · USUniversity of Michigan · US

Funding

UCLA SPORE IN PROSTATE CANCERP50CA092131 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REITER, ROBERT E · 2002 to 2023
$42.6M
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
Germ-line miRNA binding site variants as biomarkers of toxicity and response to checkpoint inhibitionR01CA238998 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WEIDHAAS, JOANNE B · 2019 to 2023
$1.8M
NCI NIH HHS P50 CA092131NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA238998
6 · The paper itself

Abstract

Gleason grade group (GG) 5 prostate cancer has been associated with an aggressive natural history, and retrospective data support a role for treatment intensification. However, clinical outcomes remain heterogeneous in this cohort, and intensified treatments carry an increased risk of adverse events. We sought to explore the transcriptomic heterogeneity of GG 5 tumors by querying transcriptomic data from the tumors of 2138 patients with GG 5 disease who underwent prostatectomy. Four distinct consensus clusters were identified with respect to differential transcriptional activation of hallmark pathways, with distinct molecular subtyping profiles and different average genomic risks (AGRs). One cluster, accounting for 325 tumors (15.2% of the population), was enriched for genes related to the cell cycle/proliferation, metabolic pathways, androgen response pathways, and DNA repair, and had a higher AGR than the other clusters (p < 0.001). This clustering, with an identification of a high genomic risk cluster, was subsequently validated in a separate cohort of 1921 patients as well as a third cohort of 201 patients. The latter cohort had outcomes available, and it was found that patients in the high genomic risk cluster had significantly worse distant metastasis-free survival than the other clusters. Tumors in this high genomic risk cluster of GG 5 disease may be particularly likely to benefit from treatment intensification. PATIENT SUMMARY: In this report, we examined differences in gene expression in tumors from men with Gleason grade group 5 prostate cancer. We identified significant diversity, with one specific subgroup of tumors associated with expression profiles that suggest a worse prognosis.

Indexed as

TranscriptomeAgedCohort StudiesGenetic VariationHumansMaleMiddle AgedNeoplasm GradingProstatic NeoplasmsBiomarkersGleason grade group 5Gleason score 10Gleason score 9Transcriptomics

Identifiers

PMID32461072
PMCPMC8954568
OpenAlexW3027025155

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.